Matinas Biopharma
MTNB
Matinas Biopharma (MTNB) earnings history
Most recent quarter
- Fiscal period
- Q3 2024
- Period end
- Sep 30, 2024
- EPS actual
- −$12.75
- EPS estimate
- −$15.83
- EPS surprise
- +19.43%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 13, 2024
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2024 | Nov 13, 2024 | −$15.83 | −$12.75 | +19.43% | $0.00 | SEC |
| Q2 2024 | Aug 14, 2024 | −$18.75 | −$15.00 | +20.00% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$22.50 | −$22.50 | +0.00% | $0.00 | SEC |
| Q4 2023 | Mar 27, 2024 | −$22.50 | −$15.00 | +33.33% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$21.79 | −$22.50 | −3.27% | $0.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$22.76 | −$22.50 | +1.15% | $0.00 | SEC |
| Q1 2023 | May 10, 2023 | −$22.50 | −$22.50 | +0.00% | $1.1M | SEC |
| Q4 2022 | Mar 15, 2023 | −$18.98 | −$15.00 | +20.95% | $1.1M | SEC |
| Q3 2022 | Nov 2, 2022 | −$22.26 | −$22.50 | −1.09% | $1.1M | — |
| Q2 2022 | Aug 11, 2022 | −$25.22 | −$22.50 | +10.78% | $1.1M | — |
| Q1 2022 | May 12, 2022 | −$20.00 | −$22.50 | −12.50% | $0.00 | — |
| Q4 2021 | Mar 8, 2022 | −$25.33 | −$22.50 | +11.18% | $0.00 | — |
| Q3 2021 | Nov 8, 2021 | −$14.59 | −$22.50 | −54.24% | $0.00 | — |
| Q2 2021 | Aug 10, 2021 | −$22.50 | −$15.00 | +33.33% | $0.00 | — |
| Q1 2021 | May 10, 2021 | −$19.76 | −$22.50 | −13.85% | $33,333.00 | — |
| Q4 2020 | Mar 29, 2021 | −$20.90 | −$22.50 | −7.68% | $62,500.00 | — |
| Q3 2020 | Nov 6, 2020 | −$26.25 | −$22.50 | +14.29% | $96,000.00 | — |
| Q2 2020 | Aug 10, 2020 | −$24.00 | −$22.50 | +6.25% | $0.00 | — |
| Q1 2020 | May 11, 2020 | −$24.00 | −$22.50 | +6.25% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Matinas Biopharma (MTNB) last report earnings?
Matinas Biopharma last reported on Nov 13, 2024, covering fiscal Q3 2024.
Did MTNB beat earnings estimates?
Yes. Matinas Biopharma reported EPS of −$12.75 for Q3 2024 against a −$15.83 estimate — a 19.43% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.